India: To Keep INN Or Out

Last Updated: 25 October 2015
Article by Sachin Bindal and Amit Koli

Ever since India opened up its patent regime in January 2005 to include product patents in the field of pharmaceuticals, the patent law in this domain has kept alive the interest of various stakeholders. This is rightly so, since India is also known as the pharmacy of the world and is a global market leader in the export of generic drugs to the United States and Japan, as well as to countries in Africa and Europe. The Indian generic pharmaceutical industry had a turnover of US$11 billion in 2010, registering a growth rate of 22 per cent.1 During 2013–2014, pharmaceutical exports stood at Rs 90 000 crores (US$14.55 billion).2 Also, India is one of the largest consumers of medicines in the world, even though accessibility of medicines across economically weaker sections remains an issue. The Indian patent regime is well equipped to balance the quid-pro-quo requirement of patents. Even though jurisprudence in this field is still evolving, recent judicial precedents have reaffirmed that this is so.

In 2013, the Indian Patent Office (IPO) proposed a requirement of disclosure of International Nonproprietary Names (INNs) in patent applications relating to pharmaceutical inventions.3 Thereafter, the IPO organized a meeting with different stakeholders to discuss the proposal and receive feedback on the feasibility and implementation of this policy. The proposal was to make the disclosure of INNs mandatory and for the Patent Rules to be amended to provide the necessary basis for this. The stakeholders put voiced their concerns both for and against the proposal. The IPO finally decided to reject the proposal at least of making this a mandatory requirement, so the Patent Rules remain unchanged. It goes to IPO's credit that the proposal of mandatory disclosure of INNs in the patent specification was removed from the recently issued guidelines for examination of pharmaceutical applications. However, the guidelines instruct the examiner to search prior art based on any INN disclosed in the specification. Further, in the case of second medical use4 inventions, the examiner is directed to ask the applicant to disclose the INN of the known substance where second medical use is claimed. In the event that the applicant does not give such information even upon request, the examiner is required to seek to ascertain the INN and to search prior art based on it.

In this article, we attempt to explore the use of INNs as a proposed tool for searching prior art and examine whether INNs would indeed make things simpler for patent examiners in India. Some of the issues were discussed during various stakeholder meetings held at the IPO, before this proposal was finally dropped.

General background of INNs

The INN or generic name is an official name given to a pharmaceutical substance, as designated by the World Health Organization (WHO). An INN identifies a pharmaceutical substance or active pharmaceutical ingredient by a unique name that is globally recognized and easy to remember, unlike International Union of Pure and Applied Chemistry (IUPAC) nomenclature. Apart from INN nomenclature, there are also various systems of nomenclature across different countries, such as British Approved Names (BANs) and United States Adopted Names (USANs) to identify pharmaceutical substance with an official nonproprietary name.5 Table 1 provides examples of INNs.

The questions

The proposal for using INN as a search tool raised a number of questions, including the following: What makes INNs suddenly a sought-after tool for searching prior art patents? Would it be beneficial for the patent examiner to have a disclosure regarding INNs? Might it not be an extra burden on applicants seeking patents in India? Is there any vested interest of any group or agency in fueling the sudden need for such disclosure in Indian applications? Would this requirement be TRIPs-compliant?

INNs as a tool for searching earlier patents

The proposal to disclose INNs was based on the premise that this would help the examiner to conduct a search of prior patents more effectively.

To examine this hypothesis, we designed a sample prior patent search5 related to the method of synthesis for aspirin. The results are shown in Table 2.

We found that search string B, which used the IUPAC name of aspirin, found two relevant results out of four documents in the domain of method of synthesis of aspirin. In fact, string A appeared to have missed two most relevant results which were found by string B (as there are no common patents between string A and B as shown above). Thus INNs did not prove to provide an effective search tool in this instance.

Further, to confirm this provisional conclusion, we designed another study for prior patent search6 in the domain of composition of rotigotine. Rotigotine is a drug that was approved in Europe for the treatment of Parkinson's disease and restless legs syndrome in 2006. For this trial, we changed the subject matter of the search (from 'method of synthesis' to 'composition'), the name of drug molecule (from 'aspirin' to 'rotigotine') and the search field (from 'title' to 'title, abstract or claims' to broaden the patent search), as there may be a presumption that aspirin is a too old a drug, and String A would nevertheless miss patents in the domain of method of synthesis (where generally the IUPAC name is disclosed in synthesis patents). However, we reached the same conclusion as mentioned above. The results are shown in Table 3.

Out of four documents captured by String F, three documents belong to same patent family which discloses composition comprising acid addition salts of rotigotine, while one remaining document talks about novel rotigotine salts. In other words, these patents or applications were not relevant to our search, as they related to salts of rotigotine and its composition but not to the composition of rotigotine as such.

Further, string D missed a few results that are highly relevant to the field of study, already captured in String E. We found that search string E, which used the IUPAC name of rotigotine, found four relevant results (US7413747B2, US20080138389A1, US6884434B1 and US20050033065A1) among 26 documents in the domain of composition of rotigotine as such. In fact, among four relevant documents, there are patents US7413747B2 and US6884434B1 listed in the Orange Book. Orange Book-listed patents are highly relevant patents that are published by the Food and Drug Administration (the US drug approval agency). Thus INNs appeared to fail as an efficient search tool to obtain the relevant prior art.

In addition, we designed one more study in the domain of the polymorph (crystalline) form of axitinib and found the same conclusion as mentioned above. The results are shown in Table 4.

Two documents captured by String I were not relevant to our domain of search. Further, string G missed a few results which are highly relevant to the field of study, already captured in String H. In other words, we found that search string H, which used the IUPAC name of axitinib, captured one Orange Book-listed patents US8791140B2 disclosing the crystalline form of axitinib and its corresponding EP and WO patent applications which was missed by String G.7

The currently available searching tools, such as molecular formulae, structural diagrams, clinical trial codes and systematic names under the IUPAC nomenclature, Chemical Abstracts Services (CAS) registry numbers etc, have been well tried and tested. These well-established tools have been recognized worldwide to be effective in searching prior art data, and no major patent office requires disclosure of INNs in the patent application.

Sometimes, there may even be a conflict between substances still being referred to with national names such as BANs, De´nominations communes franc¸aises (DCFs), Japanese Adopted Names (JANs) and USANs, which are similar in purpose to the INN. There may be cases where there will be a difference between INNs and other approved national names such as BANs, JANs or USANs. For example, Flurothyl is an approved USAN, whereas its INN is Flurotyl.8 This could lead to confusion. It is thus concluded that the requirement of disclosing INNs may create confusion in patent prosecution.

Why link patents to INNs?

Was it a good idea to link patents to INN? If it was, who should take on the burden of linking patents to INNs? Would the applicant have found it unnecessarily cumbersome to disclose the INN before filing the patent application? At best, any link between the patent and the INN should be the responsibility of regulatory bodies during the drug approval stage.

Including INNs at the time of filing the patent application

Drug patents are filed as soon as the pharmaceutical research and development (R&D) shows promise in an invention. Accordingly, compounds of interest are unlikely to have an INN at the patenting stage. Some patents actually use laboratory acronyms for naming these compounds. It is therefore a practical challenge to include the INN at the time of filing of a patent application, which is why patent applications almost never use INNs. Besides, since the international patent system does not allow for adding subject matter once the application has been filed, the inclusion of an INN does not present a viable approach.

Internationally, linking patents to INNs is done at the regulatory stage when applying for drug approval and not at the patenting stage itself. Patent linkage at the product approval stage is meant to prevent patent infringement by generics and is followed by several countries that are members of the World Trade Organization. Further, such linkage requires a closer collaboration of health regulators and the patent office.

The US Food and Drug Administration (FDA) used to link approved drug products (which had an INN) to patents on their website using a repository known as the Orange Book.9 We performed the search for 'rotigotine' (an FDA-approved drug acting as dopamine agonist indicated for the treatment of Parkinson's disease and Willis-Ekbom disease) as an INN in the Orange Book. The search results are presented below in Table 5.

Patent information corresponding to a drug product is submitted by the sponsor/applicant to the FDA, depending on the approval status of the product application. Following the product's approval, the FDA publishes the list of patents mapped with that product (which has an INN) in the Orange Book.

A few years back, a decree was published in the official Gazette of the Federal Government of Mexico, which amended the Regulations of the Health Law as well as the Regulations of the Law on Industrial Property. This new amendment imposed upon the Mexican Institute of Industrial Property (IMPI) an obligation to publish a special gazette listing those patents relating to allopathic drugs and their corresponding INNs. This new regime was brought in to benefit patent owners, as following this amendment, the Mexican health authorities would not grant health registrations for products covering the active ingredients as published in the gazette, until the expiry of the patent.10 In this case, applicants for marketing approval of pharmaceutical products are required to inform the health regulatory authorities whether or not they are the patent holder or licensee for any existing patent relevant to that product. An the applicant who does not have a patent or licence must provide a declaration that the product application does not infringe the rights of the patent holder.

The health authorities work with the IMPI to determine the patent status of the product for which there is a pending marketing application. If the search indicates that a valid patent would be infringed, the health authorities will give the applicant an opportunity to demonstrate that it has the rights to the product. In the alternative, the health authorities will reject the product application.11

Similarly, in China, the State Food and Drug Administration (SFDA) maintains two separate tracks by which it provides patent linkage for compound/composition patents:

  • The SFDA requires all applicants for marketing approval to check patent status prior to making an application, and to certify that their products do not infringe any existing patents; they must also acknowledge liability for damage resulting from any future finding of patent infringement.
  • The SFDA maintains a list of all drug product registrations by chemical names (INNs), which is available for frequent inspection by patent owners, who can check whether there are applications for marketing approval for new products that may infringe any existing patents.12

In the interest of the patent owners and in order to avoid copying of a patented drug, such linkage between patent and INNs at the regulatory stage does appear justified. The aim of the INN system has been to provide health professionals with a unique, universally available, designated name to identify each pharmaceutical substance. The existence of an international nomenclature for pharmaceutical substances, in the form of INNs, is for identification, safe prescription and dispensing of medicines to patients, and also for communication and exchange of information among health professionals. The role of INNs is mainly for regulatory and commercial purposes and not for patenting issues. Readers may also recall that, in Bayer v Cipla,13 the Indian High Court and the Indian Supreme Court clearly ruled that there can be no overlap between regulatory and patent law. This would also apply in the present context where the regulatory and commercial role of INNs should not overlap with the patent by disclosing an INN in a patent application.

What would it take to disclose an INN in a patent application?

INNs are allocated by the WHO on the advice of experts from the WHO Expert Advisory Panel on the International Pharmacopoeia and Pharmaceutical Preparations. The process of INN selection follows three main steps:

  1. a request/application is made by the applicant company;
  2. after a review of the request, a proposed INN is selected and published for comments;
  3. after a time-period for comments and objections has lapsed, the name will obtain the status of a recommended INN and will be published.

Importantly, the rules relating to the application for an INN specifically state that an INN for a substance should only be applied for once it has been tested on human subjects.

Concerns of the patent applicant

Patent applicants seeking a drug patent in India have had substantial concerns with regard to the inclusion of INNs in the patents' description. These concerns include the risk of losing novelty due to delay in obtaining an INN from the WHO; the lack of clarity as to the consequences of not including an INN in the description (even though the recent examination guidelines on pharmaceutical inventions issued by the IPO do not mandate the disclosure of INN now); possible loss of patent term, where the IPO decides to withhold the grant of a patent for want of INN disclosure; misuse by third parties due to frivolous oppositions or invalidation proceedings, particularly on the ground of s 3(d) of Indian Patents Act; and practical difficulties in specifying INNs for all possible components of a claimed composition or a Markush representation.14

Section 10(4) of the Indian Patents Act clearly defines what the specification of the patent application shall contain. The 'best method of performing the invention' requirement under s 10(4) (b) of the same Act clearly states that the applicant/inventor is entitled to protection by disclosing the best method of performing the invention. The disclosure of an INN does not appear to be a reliable source of describing an invention; nor does it provide any aid in enabling a person skilled in the art to carry out or apply the invention. It is only wise that this requirement should be dropped: it imposes a burden on the applicant, who in any event must overcome other important legal barriers before obtaining a drug patent in India.

Legally speaking, under Article 27 of the Agreement on Trade-related Aspects of Intellectual Property Rights (TRIPS), members of the said agreement cannot discriminate between different fields of technology in their patent regimes. By rejecting the proposal for mandatory requirement of disclosing an INN in the specification, India has saved itself from being potentially accused of discrimination between other technologies and pharmaceuticals, which would be contrary to TRIPS.

From sudden interest to careful thought

The sudden interest of the Indian Patent Office in require disclosure of INN in a patent application came as a surprise to patent applicants in the pharma domain. Given that debate over the patenting of pharmaceutical inventions in India is no longer restricted to legal issues but evokes serious emotive issues, the IPO was certainly faced with dilemma of having to address both. Admirably, the IPO took a reasonable and balanced view on this issue pursuant to elaborate discussions on this issue with various stakeholders. It may augur well for the patent fraternity if the IPO thoroughly researches the need and usefulness of such proposals, which have a great impact on all the stakeholders before initiating any nationwide debate.

The patent search outlined in Table 6 was performed in Total Patent Database on 15 April 2015. The Search field remains the same as Title, Abstract or claims in US, EP and WO. The same conclusion was drawn as mentioned above, ie that the strings based on INN missed the relevant results which were captured by the strings based on the IUPAC name.


* The authors thank Dr Deepa Kachroo Tiku, Partner, K & S Partners, Gurgaon, India for providing her unconditional guidance and critical comments without which this paper could not be written to its fullest. The views expressed in this article are solely those of authors alone and do not in any way represent the views of K & S Partners.

1. Aiswariya Chidambaram, 'Market Insight, Indian Generic Pharmaceuticals Market—A Snapshot' SOURCE (27 July 2012). Available at (May 05, 2015).

2. India in Business, Ministry of External Affairs, Government of India, Investment and Technology Promotion Division "Pharmaceuticals". Available at (June 03, 2015).

3. Office of the Controller General of Patents, Designs & Trade Marks, Guidelines for Examination of Patent Applications in the Field of Pharmaceuticals (October 2014) paras 5.3 and 5.4. Available at (May 03, 2015).

4. New therapeutic uses for known active ingredients

5. World Health Organization, 'Guidance on INN'. Available at (April 05, 2015).

6. The patent search was conducted using the Total Patent database on 23 December 2014. 'w/n' is a search operator used in Total Patent database that finds search terms that appear within n-number of words of each other.

7. A similar exercise was conducted with several drugs and the same conclusion was obtained. The results are presented in Table 6.

8. Kyoto University Bioinformatics Center (GenomeNet), "DRUG: D04236" Available at (June 14, 2015).

9. US Food and Drug Administration, 'Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations—Active ingredient search engine'. Available at (April 22, 2015).

10. D Sa´nchez, 'Drugs Patent Reforms Introduced', Managing Intellectual Property (April 2004). Available at (March 21, 2015).

11. Finston Consulting, LLC, 'Patent Linkage Case Studies', Report (8 October 2006) 3–4. Available at (March 15, 2015).

12. Report of US-China Joint Commission on Commerce and Trade, Medical Device and Pharmaceutical Subgroup, Pharmaceutical Task force Meeting, August 20, 2005, Beijing, China. Available at (June 03, 2015).

13. Bayer v UOI, Case Nos 7833/2008 and LPA 443/2009, Delhi High Court WP(C), paras 39–41 (Judgement pronounced on August 18, 2009); Bayer v UOI, Case No 6540/2010, Supreme Court of India Appeal (Civil) (Disposed on December 01, 2010).

14. Herein, Markush representation are chemical symbols used to indicate a collection of chemicals with similar structures. They are commonly used in chemistry texts, and also in patent claims.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on

Click to Login as an existing user or Register so you can print this article.

In association with
Up-coming Events Search
Font Size:
Mondaq on Twitter
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
Email Address
Company Name
Confirm Password
Mondaq Topics -- Select your Interests
 Law Performance
 Law Practice
 Media & IT
 Real Estate
 Wealth Mgt
Asia Pacific
European Union
Latin America
Middle East
United States
Worldwide Updates
Mondaq Ltd requires you to register and provide information that personally identifies you, including what sort of information you are interested in, for three primary purposes:
  • To allow you to personalize the Mondaq websites you are visiting.
  • To enable features such as password reminder, newsletter alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our information providers who provide information free for your use.
  • Mondaq (and its affiliate sites) do not sell or provide your details to third parties other than information providers. The reason we provide our information providers with this information is so that they can measure the response their articles are receiving and provide you with information about their products and services.
    If you do not want us to provide your name and email address you may opt out by clicking here
    If you do not wish to receive any future announcements of products and services offered by Mondaq you may opt out by clicking here

    Terms & Conditions and Privacy Statement (the Website) is owned and managed by Mondaq Ltd and as a user you are granted a non-exclusive, revocable license to access the Website under its terms and conditions of use. Your use of the Website constitutes your agreement to the following terms and conditions of use. Mondaq Ltd may terminate your use of the Website if you are in breach of these terms and conditions or if Mondaq Ltd decides to terminate your license of use for whatever reason.

    Use of

    You may use the Website but are required to register as a user if you wish to read the full text of the content and articles available (the Content). You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these terms & conditions or with the prior written consent of Mondaq Ltd. You may not use electronic or other means to extract details or information about’s content, users or contributors in order to offer them any services or products which compete directly or indirectly with Mondaq Ltd’s services and products.


    Mondaq Ltd and/or its respective suppliers make no representations about the suitability of the information contained in the documents and related graphics published on this server for any purpose. All such documents and related graphics are provided "as is" without warranty of any kind. Mondaq Ltd and/or its respective suppliers hereby disclaim all warranties and conditions with regard to this information, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. In no event shall Mondaq Ltd and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use or performance of information available from this server.

    The documents and related graphics published on this server could include technical inaccuracies or typographical errors. Changes are periodically added to the information herein. Mondaq Ltd and/or its respective suppliers may make improvements and/or changes in the product(s) and/or the program(s) described herein at any time.


    Mondaq Ltd requires you to register and provide information that personally identifies you, including what sort of information you are interested in, for three primary purposes:

    • To allow you to personalize the Mondaq websites you are visiting.
    • To enable features such as password reminder, newsletter alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
    • To produce demographic feedback for our information providers who provide information free for your use.

    Mondaq (and its affiliate sites) do not sell or provide your details to third parties other than information providers. The reason we provide our information providers with this information is so that they can measure the response their articles are receiving and provide you with information about their products and services.

    Information Collection and Use

    We require site users to register with Mondaq (and its affiliate sites) to view the free information on the site. We also collect information from our users at several different points on the websites: this is so that we can customise the sites according to individual usage, provide 'session-aware' functionality, and ensure that content is acquired and developed appropriately. This gives us an overall picture of our user profiles, which in turn shows to our Editorial Contributors the type of person they are reaching by posting articles on Mondaq (and its affiliate sites) – meaning more free content for registered users.

    We are only able to provide the material on the Mondaq (and its affiliate sites) site free to site visitors because we can pass on information about the pages that users are viewing and the personal information users provide to us (e.g. email addresses) to reputable contributing firms such as law firms who author those pages. We do not sell or rent information to anyone else other than the authors of those pages, who may change from time to time. Should you wish us not to disclose your details to any of these parties, please tick the box above or tick the box marked "Opt out of Registration Information Disclosure" on the Your Profile page. We and our author organisations may only contact you via email or other means if you allow us to do so. Users can opt out of contact when they register on the site, or send an email to with “no disclosure” in the subject heading

    Mondaq News Alerts

    In order to receive Mondaq News Alerts, users have to complete a separate registration form. This is a personalised service where users choose regions and topics of interest and we send it only to those users who have requested it. Users can stop receiving these Alerts by going to the Mondaq News Alerts page and deselecting all interest areas. In the same way users can amend their personal preferences to add or remove subject areas.


    A cookie is a small text file written to a user’s hard drive that contains an identifying user number. The cookies do not contain any personal information about users. We use the cookie so users do not have to log in every time they use the service and the cookie will automatically expire if you do not visit the Mondaq website (or its affiliate sites) for 12 months. We also use the cookie to personalise a user's experience of the site (for example to show information specific to a user's region). As the Mondaq sites are fully personalised and cookies are essential to its core technology the site will function unpredictably with browsers that do not support cookies - or where cookies are disabled (in these circumstances we advise you to attempt to locate the information you require elsewhere on the web). However if you are concerned about the presence of a Mondaq cookie on your machine you can also choose to expire the cookie immediately (remove it) by selecting the 'Log Off' menu option as the last thing you do when you use the site.

    Some of our business partners may use cookies on our site (for example, advertisers). However, we have no access to or control over these cookies and we are not aware of any at present that do so.

    Log Files

    We use IP addresses to analyse trends, administer the site, track movement, and gather broad demographic information for aggregate use. IP addresses are not linked to personally identifiable information.


    This web site contains links to other sites. Please be aware that Mondaq (or its affiliate sites) are not responsible for the privacy practices of such other sites. We encourage our users to be aware when they leave our site and to read the privacy statements of these third party sites. This privacy statement applies solely to information collected by this Web site.

    Surveys & Contests

    From time-to-time our site requests information from users via surveys or contests. Participation in these surveys or contests is completely voluntary and the user therefore has a choice whether or not to disclose any information requested. Information requested may include contact information (such as name and delivery address), and demographic information (such as postcode, age level). Contact information will be used to notify the winners and award prizes. Survey information will be used for purposes of monitoring or improving the functionality of the site.


    If a user elects to use our referral service for informing a friend about our site, we ask them for the friend’s name and email address. Mondaq stores this information and may contact the friend to invite them to register with Mondaq, but they will not be contacted more than once. The friend may contact Mondaq to request the removal of this information from our database.


    From time to time Mondaq may send you emails promoting Mondaq services including new services. You may opt out of receiving such emails by clicking below.

    *** If you do not wish to receive any future announcements of services offered by Mondaq you may opt out by clicking here .


    This website takes every reasonable precaution to protect our users’ information. When users submit sensitive information via the website, your information is protected using firewalls and other security technology. If you have any questions about the security at our website, you can send an email to

    Correcting/Updating Personal Information

    If a user’s personally identifiable information changes (such as postcode), or if a user no longer desires our service, we will endeavour to provide a way to correct, update or remove that user’s personal data provided to us. This can usually be done at the “Your Profile” page or by sending an email to

    Notification of Changes

    If we decide to change our Terms & Conditions or Privacy Policy, we will post those changes on our site so our users are always aware of what information we collect, how we use it, and under what circumstances, if any, we disclose it. If at any point we decide to use personally identifiable information in a manner different from that stated at the time it was collected, we will notify users by way of an email. Users will have a choice as to whether or not we use their information in this different manner. We will use information in accordance with the privacy policy under which the information was collected.

    How to contact Mondaq

    You can contact us with comments or queries at

    If for some reason you believe Mondaq Ltd. has not adhered to these principles, please notify us by e-mail at and we will use commercially reasonable efforts to determine and correct the problem promptly.

    By clicking Register you state you have read and agree to our Terms and Conditions